Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03867175 · ClinicalTrials.gov registry record · Phase 3
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
A Phase 3 study of Metastatic Lung Cancer and Stage IV Lung Cancer, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT03867175 is a Phase 3 study of Metastatic Lung Cancer and Stage IV Lung Cancer that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 5 participants, below the 175-participant average among 10 other Metastatic Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03867175, a Phase 3 study of Metastatic Lung Cancer and Stage IV Lung Cancer, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase III trial studies immunotherapy and stereotactic body radiation therapy to see how well it works compared with immunotherapy alone after first-line systemic therapy (therapy that goes throughout the body) in treating patients with stage IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving immunotherapy with stereotactic body radiation therapy may work better than immunotherapy alone in treating patients with non-small cell lung cancer.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- RADIATION Stereotactic Body Radiation Therapy
Study Locations (1)
North Carolina
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2025-04-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03867175
The ClinicalTrials.gov registry entry for NCT03867175 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 175-participant average among 10 other Metastatic Lung Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03867175 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03867175 about?
NCT03867175 is a clinical study titled "Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer". This phase III trial studies immunotherapy and stereotactic body radiation therapy to see how well it works compared with immunotherapy alone after first-line systemic therapy (therapy that goes throughout the body) in treating patients with stage IV non-small cell lung cancer. Immunotherapy with mo...
What is the current status of trial NCT03867175?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2019-06-24. Estimated completion is 2025-04-21.
What conditions does trial NCT03867175 study?
This clinical trial studies the following conditions: Metastatic Lung Cancer, Stage IV Lung Cancer.
What interventions are being tested in trial NCT03867175?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Stereotactic Body Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03867175?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03867175 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
-
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.